Corrected Data. In the Original Contribution entitled "Major Cardiovascular Events in
Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive
and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)" published
in the April 19, 2000, issue of THE JOURNAL (2000;283:1967-1975), data that
were reported have since been corrected. The original reported number of 42 448
participants and 625 sites changed because 30 patients with poor documentation
of informed consent were excluded. This also changed the original reported
numbers of 15 268 participants in the chlorthalidone group and 9067 participants
in the doxazosin group (a total of 24 335) to 15 255 and 9061, respectively
(a total of 24 316). In addition, the original article reported a sample
size of 10 337 for the lipid-lowering trial component of ALLHAT. This
was a typographical error and should have been 10 357. However, due to
the deletion of participants from the database, this number is now 10 355.
In addition, losses to follow-up were reported as 501 patients in the
chlorthalidone group and 338 patients in the doxazosin group. This has been
changed to losses of 545 patients and 361 patients, respectively, because
the authors modified the definition of loss to follow-up. Originally, the
definition was based on declaration of loss by a clinic site. The new definition
includes this plus vital status unknown at trial closeout, the period of October
15, 1999, through February 15, 2000.
Deaths were ascertained through February 15, 2000, by clinic report
or by match with an entry in databases from the Center for Medicare and Medicaid
Services, the Department of Veterans Affairs, the National Death Index, or
the Social Security Administration with a confirmatory death certificate.
The additional lost individuals were not known to be dead or to have had a
closeout visit after October 15, 1999. The authors identified additional deaths
in both the doxazosin (n = 769) and chlorthalidone (n = 1258) groups before
the cutoff date of February 15, 2000.
Despite these changes, the outcome analyses remain essentially the same
and all statistically significant results remain so.
Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)—Correction. JAMA. 2002;288(23):2976. doi:10.1001/jama.288.23.2976